New Injectable HIV Prevention Access Expands
A new regional procurement pathway increases access to a twice-yearly HIV prevention drug for 14 countries.
Updated on Oct. 20, 2026 in Sexual Health
Live Poll
Do you believe increasing access to new medical technologies is the best way to improve public health?
The Pan American Health Organization has established a new procurement pathway to supply the HIV prevention medication lenacapavir to 14 countries in Latin America and the Caribbean. This initiative aims to address the region's 140,000 annual new HIV infections by improving access to the twice-yearly injectable medication.
Why it matters
This agreement bridges a critical gap in HIV prevention access, potentially accelerating progress toward ending HIV as a public health threat by 2030. By leveraging regional procurement funds, health programs may integrate this high-efficacy option more efficiently into national services.
Clinical trials for lenacapavir demonstrated almost 100 percent efficacy in preventing HIV infection. Whether this level of protection will be sustained in large-scale national deployment remains to be observed.
The players
Pan American Health Organization
The international public health agency working to improve health and living standards in the Americas.
Gilead Sciences
A research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines, including HIV therapies.
The details
Lenacapavir functions as a twice-yearly injectable pre-exposure prophylaxis that provides long-acting protection against HIV. Under the new agreement, countries will procure the medication through the Pan American Health Organization's Regional Revolving Funds, which helps streamline distribution. Future efforts include a technology-transfer process initiated by Gilead Sciences to facilitate local production in Brazil, which could further stabilize the regional supply chain.
Timeline
2025: WHO recommended lenacapavir for HIV prevention.
October 20, 2026: PAHO announced the new procurement pathway agreement.
2030: Target date to end HIV as a public health problem.
Health Landscape
This procurement initiative follows the strategic framework established by the WHO's 2025 HIV prevention guidelines. It signals a move toward integrating high-efficacy, long-acting injectables into the standard public health response to manage the HIV epidemic.
This development marks a significant shift in the availability of long-acting HIV prevention for populations in the affected regions. Individuals interested in twice-yearly injectable prophylaxis should discuss the timing of local availability and clinical eligibility with their healthcare provider.
The takeaway
Lenacapavir represents a major advancement as a long-acting injectable option for HIV prevention that requires only two doses per year. Residents in the impacted regions should talk to their physician about whether injectable prophylaxis is a suitable addition to their personal health management strategy.
Further reading
Learn more about advancements in Sexual Health and the latest developments in HIV prevention tools.
Source note: This article includes information reported by Caribbeannewsglobal.
Live Poll
Do you believe increasing access to new medical technologies is the best way to improve public health?
